We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Danaher Corporation | NYSE:DHR | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.05 | -0.02% | 246.84 | 249.435 | 242.66 | 248.99 | 2,780,503 | 01:00:00 |
By Dave Sebastian
Danaher Corp.'s profit and sales for the third quarter grew, the company said Thursday.
For the quarter ended Oct. 2, the conglomerate on Thursday posted net income before preferred dividends of $883.5 million, or $1.16 a share, compared with $668 million, or 84 cents a share, in the year-ago period.
One of the company's units earlier this month said its Covid-19 antibody test got emergency use authorization from the Food and Drug Administration. The company didn't immediately provide details of Covid-19 effects in its earnings release Thursday.
Adjusted earnings were $1.72 a share. Analysts polled by FactSet were looking for earnings of $1.01 a share, or $1.36 a share on an adjusted basis.
Sales rose to $5.88 billion from $4.38 billion in the comparable quarter last year. Analysts were looking for $5.51 billion. Core revenue, including Cytiva, rose 14%. The company had expected third-quarter core revenue growth, including Cytiva, to be in the mid- to high-single digit range.
Danaher said it expects fourth-quarter core revenue growth, including Cytiva, to be in the low-double digit range.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
October 22, 2020 06:39 ET (10:39 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Danaher Chart |
1 Month Danaher Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions